Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

NCT00783094 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: Tadalafil 2.5 mg
DRUG: Tadalafil 5 mg
DRUG: Placebo

Sponsor

Eli Lilly and Company